July 14, 2008
Merck’s Cholesterol Drug Granted European Approval
Merck Sharp & Dohme has announced that Tredaptive 1g/20mg modified-release tablets, a new lipid-modifying therapy for patients with dyslipidemia and primary hypercholesterolemia, has received marketing approval in the EU, Iceland and Norway.
Merck Sharp & Dohme's Tredaptive combines nicotinic acid and laropiprant, a novel flushing pathway inhibitor. In clinical studies involving more than 4,700 patients, Tredaptive reduced LDL-cholesterol (LDL-C, or 'bad' cholesterol) levels, raised HDL-cholesterol (HDL-C, or 'good' cholesterol) levels and decreased triglycerides.
Stefan Oschmann, president of Merck Sharp & Dohme, Europe, Middle East, Africa and Canada, said: "The approval of Tredaptive in the EU further reinforces our long-standing commitment to the cardiovascular area by bringing novel and innovative therapies to patients."